Combat Medical

Bladder and colorectal cancers are the fifth and ninth most common cancers in the world (2012). Their current standard of treatment is cold chemotherapy which, when coming into contact with cancer cells, have a low absorption rate. This ineffectiveness results in a high recurrence of the disease and an increasingly expensive cost of treatment.

Combat Medical’s proprietary technology (5 patents, 3 granted), which is CE marked and patent protected, uses heat to increase chemotherapy absorption rate by up to 10 times as well as stimulate the patient's natural immune response. This significantly reduces both recurrence rates and negative side effects of chemotherapy, whilst improving the chances of survival.

Key Investment Highlights

  • First to market with a superior quality mobile gaming solution for recruitment

  • Disrupting the psychometric selection industry, estimated to have reached $2.5 billion in 2014

  • Significant client traction including large corporations

  • Experienced management team led by Robert Newry who has spent his career in the technology and software sectors